Zenobio Aguila, MD
Internal Medicine · Venice, FLNPI 1205882164
Payments from drug & device makers
Across 196 payments — averaging $16.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$333
- Novo Nordisk$282
- Bayer$256
- Pfizer$245
- AstraZeneca$229
- GSK$219
- plus $2K from 25 others
What the payments were for
- Food & beverage$3,209100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 21 | $333 |
| Novo Nordisk | 14 | $282 |
| Bayer | 11 | $256 |
| Pfizer | 17 | $245 |
| AstraZeneca | 13 | $229 |
| GSK | 18 | $219 |
| Boehringer Ingelheim | 18 | $210 |
| AbbVie(2 entities) | 14 | $208 |
| Lilly USA, LLC | 11 | $173 |
| Merck | 14 | $165 |
| LEO Pharma Inc. | 1 | $125 |
| Astellas Pharma US Inc | 6 | $99 |
| Exact Sciences | 3 | $83 |
| Sunovion Pharmaceuticals Inc. | 5 | $69 |
| Johnson & Johnson | 4 | $67 |
| Amarin Pharma, Inc. | 3 | $51 |
| Xeris Pharmaceuticals, Inc. | 3 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $43 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $41 |
| Abbott | 2 | $41 |
| Phathom Pharmaceuticals, Inc. | 2 | $39 |
| Dexcom, Inc. | 2 | $36 |
| Nevro Corp. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ADBRY$125
How this compares
$3,209 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 143 | $171,211 |
| OzempicSemaglutide | 98 | $146,401 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 77 | $98,212 |
| Xeljanz XrTofacitinib Citrate | 16 | $85,510 |
| JardianceEmpagliflozin | 52 | $65,133 |
| XareltoRivaroxaban | 39 | $51,170 |
| JanuviaSitagliptin Phosphate | 50 | $51,034 |
| XifaxanRifaximin | 12 | $36,924 |
| TrulicityDulaglutide | 22 | $29,689 |
| MyrbetriqMirabegron | 15 | $19,239 |
| Repatha SureclickEvolocumab | 16 | $17,292 |
| SymbicortBudesonide/Formoterol Fumarate | 29 | $12,146 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 27 | $11,523 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $10,822 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $10,288 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $245 | $171,211143 claims |
| Novo NordiskOzempic | $282 | $146,40198 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $219 | $120,023116 claims |
| Boehringer IngelheimJardiance | $210 | $65,13352 claims |
| Johnson & JohnsonXarelto | $67 | $51,17039 claims |
| MerckJanuvia | $165 | $51,03450 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $15 | $36,92412 claims |
| Lilly USA, LLCTrulicity | $173 | $29,68922 claims |
| Astellas Pharma US IncMyrbetriq | $99 | $19,23915 claims |
| AstraZenecaSymbicort, Brilinta | $229 | $19,00740 claims |
| AbbVieSynthroid | $208 | $3,92548 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Venice
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.